carnitine has been researched along with Cirrhosis in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD." | 9.19 | The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014) |
| " Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine." | 7.85 | From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017) |
| " Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ." | 7.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
| "L-carnitine supplementation attenuates cardiac fibrosis by increasing prostacyclin production through arachidonic acid pathway, and may be a promising therapeutic option for HFpEF." | 7.78 | L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. ( Aizawa, Y; Kamimura, D; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Sakata, Y; Soga, T; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K, 2012) |
| "l-Carnitine (LC) plays an essential role in the β-oxidation of long-chain fatty acids in lipid metabolism." | 5.39 | L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013) |
| "Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD." | 5.19 | The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014) |
| " Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine." | 3.85 | From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017) |
| " The aim of the study was to investigate the role of MMPs and their inhibitors (TIMPs), in the pathogenesis of choline deficiency-induced cardiomyopathy, and the way they are affected by carnitine supplementation." | 3.83 | Immunohistochemical determination of the extracellular matrix modulation in a rat model of choline-deprived myocardium: the effects of carnitine. ( Giannopoulou, I; Karkalousos, P; Kriebardis, A; Lazaris, A; Liapi, C; Panayiotides, I; Papavdi, A; Perelas, A; Strilakou, A, 2016) |
| " Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ." | 3.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
| "L-carnitine supplementation attenuates cardiac fibrosis by increasing prostacyclin production through arachidonic acid pathway, and may be a promising therapeutic option for HFpEF." | 3.78 | L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. ( Aizawa, Y; Kamimura, D; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Sakata, Y; Soga, T; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K, 2012) |
| "Liver fibrosis was apparent at 20 days and 13 weeks." | 1.48 | Maternal L-carnitine supplementation improves glucose and lipid profiles in female offspring of dams exposed to cigarette smoke. ( Al-Odat, I; Chan, YL; Chen, H; McGrath, KC; Oliver, BG; Pollock, CA; Saad, S, 2018) |
| "The study investigates the effects of choline deficiency on myocardial performance in adult rats and the possible modifications after carnitine administration." | 1.39 | Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine. ( Douzis, ICh; Karkalousos, PL; Lazaris, AC; Liapi, CA; Mourouzis, IS; Pantos, CI; Perelas, AI; Strilakou, AA; Stylianaki, AT, 2013) |
| "l-Carnitine (LC) plays an essential role in the β-oxidation of long-chain fatty acids in lipid metabolism." | 1.39 | L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Emran, T | 1 |
| Chowdhury, NI | 1 |
| Sarker, M | 1 |
| Bepari, AK | 1 |
| Hossain, M | 1 |
| Rahman, GMS | 1 |
| Reza, HM | 1 |
| Ottria, A | 1 |
| Hoekstra, AT | 1 |
| Zimmermann, M | 1 |
| van der Kroef, M | 1 |
| Vazirpanah, N | 1 |
| Cossu, M | 1 |
| Chouri, E | 1 |
| Rossato, M | 1 |
| Beretta, L | 1 |
| Tieland, RG | 1 |
| Wichers, CGK | 1 |
| Stigter, E | 1 |
| Gulersonmez, C | 1 |
| Bonte-Mineur, F | 1 |
| Berkers, CR | 1 |
| Radstake, TRDJ | 1 |
| Marut, W | 1 |
| Zhao, HY | 1 |
| Li, HY | 1 |
| Jin, J | 1 |
| Jin, JZ | 1 |
| Zhang, LY | 1 |
| Xuan, MY | 1 |
| Jin, XM | 1 |
| Jiang, YJ | 1 |
| Zheng, HL | 1 |
| Jin, YS | 1 |
| Jin, YJ | 1 |
| Choi, BS | 1 |
| Yang, CW | 1 |
| Piao, SG | 1 |
| Li, C | 1 |
| Chen, YC | 1 |
| Cheng, CY | 1 |
| Liu, CT | 1 |
| Sue, YM | 1 |
| Chen, TH | 1 |
| Hsu, YH | 1 |
| Huang, NJ | 1 |
| Chen, CH | 1 |
| Chou, HC | 1 |
| Wen, LL | 1 |
| Chang, CC | 1 |
| Lin, CY | 1 |
| Jin, L | 1 |
| Juan, SH | 1 |
| Saad, S | 1 |
| Al-Odat, I | 1 |
| Chan, YL | 1 |
| McGrath, KC | 1 |
| Pollock, CA | 1 |
| Oliver, BG | 1 |
| Chen, H | 2 |
| Chen, DQ | 1 |
| Cao, G | 1 |
| Argyopoulos, CP | 1 |
| Yu, H | 1 |
| Su, W | 1 |
| Chen, L | 1 |
| Samuels, DC | 1 |
| Zhuang, S | 1 |
| Bayliss, GP | 1 |
| Zhao, S | 1 |
| Yu, XY | 1 |
| Vaziri, ND | 1 |
| Wang, M | 1 |
| Liu, D | 1 |
| Mao, JR | 1 |
| Ma, SX | 1 |
| Zhao, J | 1 |
| Zhang, Y | 1 |
| Shang, YQ | 1 |
| Kang, H | 1 |
| Ye, F | 1 |
| Cheng, XH | 1 |
| Li, XR | 1 |
| Zhang, L | 1 |
| Meng, MX | 1 |
| Guo, Y | 1 |
| Zhao, YY | 1 |
| Strilakou, AA | 1 |
| Lazaris, AC | 1 |
| Perelas, AI | 1 |
| Mourouzis, IS | 1 |
| Douzis, ICh | 1 |
| Karkalousos, PL | 1 |
| Stylianaki, AT | 1 |
| Pantos, CI | 1 |
| Liapi, CA | 1 |
| Takeshita, Y | 1 |
| Takamura, T | 1 |
| Honda, M | 1 |
| Kita, Y | 1 |
| Zen, Y | 1 |
| Kato, K | 1 |
| Misu, H | 1 |
| Ota, T | 1 |
| Nakamura, M | 1 |
| Yamada, K | 1 |
| Sunagozaka, H | 1 |
| Arai, K | 1 |
| Yamashita, T | 2 |
| Mizukoshi, E | 1 |
| Kaneko, S | 1 |
| Zambrano, S | 2 |
| Blanca, AJ | 2 |
| Ruiz-Armenta, MV | 2 |
| Miguel-Carrasco, JL | 2 |
| Arévalo, M | 2 |
| Mate, A | 2 |
| Vázquez, CM | 2 |
| Nishikawa, H | 1 |
| Osaki, Y | 1 |
| Strilakou, A | 1 |
| Perelas, A | 1 |
| Lazaris, A | 1 |
| Papavdi, A | 1 |
| Karkalousos, P | 1 |
| Giannopoulou, I | 1 |
| Kriebardis, A | 1 |
| Panayiotides, I | 1 |
| Liapi, C | 1 |
| Kolwicz, SC | 1 |
| Olson, DP | 1 |
| Marney, LC | 1 |
| Garcia-Menendez, L | 1 |
| Synovec, RE | 1 |
| Tian, R | 1 |
| Omori, Y | 1 |
| Ohtani, T | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Takeda, Y | 1 |
| Tamaki, S | 1 |
| Tsukamoto, Y | 1 |
| Kamimura, D | 1 |
| Aizawa, Y | 1 |
| Miwa, T | 1 |
| Komuro, I | 1 |
| Soga, T | 1 |
| Yamamoto, K | 1 |
| Vázquez, MJ | 1 |
| Kao, HJ | 1 |
| Cheng, CF | 1 |
| Chen, YH | 1 |
| Hung, SI | 1 |
| Huang, CC | 1 |
| Millington, D | 1 |
| Kikuchi, T | 1 |
| Wu, JY | 1 |
| Chen, YT | 1 |
| Shirazi, M | 1 |
| Noorafshan, A | 1 |
| Kroup, M | 1 |
| Tanideh, N | 1 |
| Kobayashi, A | 1 |
| Yamazaki, N | 1 |
| Miura, K | 1 |
| Shirasawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carnitine and Cirrhosis
| Article | Year |
|---|---|
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis.
Topics: Carcinoma, Hepatocellular; Carnitine; Electric Impedance; Fibrosis; Hand Strength; Hepatitis C, Chro | 2015 |
1 trial available for carnitine and Cirrhosis
| Article | Year |
|---|---|
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Area Under Curve; Azetidines; Biopsy; Carnitine; Cholesterol; Ezetim | 2014 |
16 other studies available for carnitine and Cirrhosis
| Article | Year |
|---|---|
L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Disease Models, Animal; Fibrosis; Inflam | 2021 |
Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients.
Topics: Adult; Aged; Carnitine; Cohort Studies; Cytokines; Dendritic Cells; Etoposide; Fatty Acids; Female; | 2020 |
L-carnitine treatment attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
Topics: Animals; Carnitine; Fibrosis; Hydrogen Peroxide; Kidney; Phosphatidylinositol 3-Kinases; Rats; Rats, | 2021 |
Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice.
Topics: Animals; Apoptosis; Biomarkers; Carnitine; Cell Line; Disease Models, Animal; Drug Therapy, Combinat | 2021 |
From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate.
Topics: Acetylation; Alkanesulfonic Acids; Animals; Carnitine; Cell Line; Cell Movement; Cytoprotection; Dis | 2017 |
Maternal L-carnitine supplementation improves glucose and lipid profiles in female offspring of dams exposed to cigarette smoke.
Topics: Animals; Biomarkers; Carnitine; Cigarette Smoking; Dietary Supplements; Female; Fibrosis; Glucose; L | 2018 |
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea | 2019 |
Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine.
Topics: Animals; Cardiotonic Agents; Carnitine; Choline Deficiency; Dietary Supplements; Edema, Cardiac; Fib | 2013 |
L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ.
Topics: Animals; Carnitine; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Cytoprotection; Dise | 2014 |
Immunohistochemical determination of the extracellular matrix modulation in a rat model of choline-deprived myocardium: the effects of carnitine.
Topics: Administration, Oral; Animals; Cardiomyopathies; Carnitine; Choline Deficiency; Disease Models, Anim | 2016 |
Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy.
Topics: Acetyl-CoA Carboxylase; Animals; Aorta; Blotting, Western; Cardiomegaly; Carnitine; Constriction, Pa | 2012 |
L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease.
Topics: Aged; Animals; Carnitine; Delta-5 Fatty Acid Desaturase; Electrophoresis, Capillary; Epoprostenol; F | 2012 |
L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression.
Topics: Animals; Antihypertensive Agents; Carnitine; Collagen Type I; Collagen Type II; Connective Tissue Gr | 2013 |
ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit.
Topics: Adipose Tissue; Animals; Base Sequence; Blotting, Western; Carnitine; Chromosome Mapping; Ethylnitro | 2006 |
Comparison of the effects of captopril, tamoxifen and L-carnitine on renal structure and fibrosis after total unilateral ureteral obstruction in the rat.
Topics: Animals; Captopril; Carnitine; Female; Fibrosis; Kidney; Rats; Rats, Sprague-Dawley; Tamoxifen; Uret | 2007 |
Effects of L-carnitine and verapamil on myocardial carnitine concentration and histopathology of Syrian hamster BIO 14.6.
Topics: Animals; Calcinosis; Cardiomyopathies; Carnitine; Cricetinae; Fibrosis; Mesocricetus; Myocardium; Ne | 1986 |